Catalyst Biosciences Announces Appointment of Edward Williams to its Board of Directors
December 14 2017 - 8:30AM
Former Novo Nordisk Executive Strengthens
Catalyst’s Hemophilia Expertise
Catalyst Biosciences, Inc. (Nasdaq:CBIO), a clinical-stage
biopharmaceutical company focused on developing novel medicines to
address hematology indications, today announced the appointment of
Edward Williams to the board of directors, effective Jan. 1, 2018.
“The appointment of Mr. Williams to our board
provides substantial hematology industry experience to our
company,” said Nassim Usman, Ph.D., president and chief executive
officer of Catalyst. “Mr. Williams has a deep understanding of the
hemophilia space and a proven track record of driving company
growth and bringing therapeutic candidates to commercial stage in
highly competitive markets across a multitude of therapeutic areas.
Our recent board additions of Edward Williams and Andrea Hunt, who
joined our board in October 2017 and was previously responsible for
Shire’s hemophilia programs, are timely as we advance our
hemophilia programs through later-stage clinical studies.”
Mr. Williams was most recently senior vice
president of biopharmaceuticals at Novo Nordisk Inc., where he was
responsible for the general management of all aspects of the
biotechnology business for the U.S. in three therapeutic areas,
including hemophilia. Prior to Novo Nordisk, Mr. Williams was vice
president of sales in the Respiratory and Dermatology Business Unit
at Novartis Pharmaceuticals Corp., where he ran all sales aspects
of the respiratory and dermatology businesses. Before joining
Novartis, Mr. Williams held numerous sales and marketing positions
of increasing responsibility for more than 20 years at Pharmacia
& Upjohn Company (acquired by Pfizer in 2002). Mr. Williams
served on the board of Biotechnology Innovation Organization (BIO),
the National Sales Network, Basic Supply Company, Inc., has been
recognized as Industry Leader of the Year by the National
Hemophilia Foundation, and chaired fundraising for the Boys &
Girls Club of Trenton/Mercer County. Mr. Williams earned his B.S.
in biology and chemistry from Marshall University.
Dr. Barry Selick, who has been a Catalyst board
member since 2003 and chairman since 2006, will step down from the
board effective Feb. 15, 2018. Dr. Selick was recently named vice
chancellor of business development, innovation and partnerships at
the University of California, San Francisco. Current board member
Augustine Lawlor will replace Dr. Selick as chairman.
“We thank Dr. Selick for his many contributions
to Catalyst as both a member and chair of our board of directors,
and we welcome Mr. Lawlor as our new chair,” said Dr. Usman.
About Catalyst
Catalyst is a clinical-stage biopharmaceutical
company focused on developing novel medicines to address hematology
indications. Catalyst is focused on the field of hemostasis,
including the subcutaneous prophylaxis of hemophilia and
facilitating surgery in individuals with hemophilia. For more
information, please visit www.catalystbiosciences.com.
Forward-Looking Statements
This press release contains forward-looking
statements that involve substantial risks and uncertainties. All
statements, other than statement of historical facts, included in
this press release regarding our strategy and plans to develop
novel medicines to address hematology indications. Actual results
or events could differ materially from the plans and expectations
and projections disclosed in these forward-looking statements.
Various important factors could cause actual results or events to
differ materially from the forward-looking statements that Catalyst
makes, including, but not limited to, the risk that our clinical
trials and enrollment may be delayed and may not have satisfactory
outcomes, that human trials will not replicate the results from
preclinical studies, that potential adverse effects may arise from
the testing or use of Catalyst’s products, including the generation
of antibodies, the risk that costs required to develop or
manufacture Catalyst’s products will be higher than anticipated,
competition, and other factors described in the “Risk Factors”
section of the Company’s most recent Quarterly Report on Form 10-Q
filed with the SEC on November 2, 2017. Catalyst does not
assume any obligation to update any forward-looking statements,
except as required by law.
Contacts:
Corporate Fletcher PayneCFO, Catalyst
Biosciences+1.650.871.0761investors@catbio.com
InvestorsAndrew McDonald, Ph.D.LifeSci
Advisors+1.646.597.6987Andrew@lifesci.com
MediaJosephine Belluardo, Ph.D.LifeSci Public
Relations+1.646.751.4361jo@lifescipublicrelations.com
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Apr 2023 to Apr 2024